Barclays Maintains Overweight on Lumexa Imaging Hldgs, Lowers Price Target to $9
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and lowers the price target from $15 to $9.
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and lowers the price target from $15 to $9.